EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The molecular basis of intrinsic resistance to azoles in Rhizopus arrhizus

Michaela Lackner iD, Stephanie Toepfer iD, Mikhail V Keniya, Carlos Lax, Francisco E Nicolas, Victoriano Garre iD, Christoph Müller iD, Katharina Rosam, Lisa-Maria Zenz, Lucia Cesarini, Ulrike Binder, Joel D A Tyndall und 1 weitere

Antimicrobial Agents and Chemotherapy · 2026

DOI: 10.1128/aac.01337-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Michaela Lackner und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Rhizopus, Antifungal Agents, Azoles, Drug Resistance, Fungal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundación Séneca, Health Research Council of New Zealand, Royal Society of New Zealand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The fungal disease mucormycosis, while generally regarded as rare and not transmitted between individuals, has become increasingly prevalent in disaster areas, among the immunocompromised, and in diabetics especially in response to COVID-19. Treatment options are limited. These include debridement of necrotizing tissue followed by complicated multicomponent therapies with amphotericin B and selected azole drugs, usually having poor outcomes. Mucormycetes are intrinsically resistant to the widely used short-tailed azole drugs fluconazole and voriconazole, but susceptible to the long-tailed, though expensive, azole posaconazole. Knowledge of the crystal structure of Saccharomyces cerevisiae sterol 14α-demethylase (Erg11, Cyp51) led to the hypothesis that this pattern of intrinsic azole resistance and susceptibility is due to the Rhizopus arrhizus CYP51-F5 isoform residues F129 and A291, while the CYP51-F1 isoform residues Y127 and V291 confer susceptibility to both short- and long-tailed azole drugs. The heterologous overexpression of individual recombinant R. arrhizus CYP51 isoforms in a S. cerevisiae host, with or without the cognate NADPH-cytochrome P450 reductase (RaCPR), and selective genetic modification of CYP51-F5 have tested this hypothesis. Complementary gene deletion experiments in Rhizopus microsporus confirm that the amino acid residues that align with R. arrhizus CYP51-F5 F129 and A291 determine the resistance or susceptibility pattern of R. arrhizus to short-, medium-, and long-tailed azoles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RhizopusAntifungal AgentsAzolesDrug Resistance, FungalSterol 14-DemethylaseMicrobial Sensitivity TestsSaccharomyces cerevisiaeFungal ProteinsTriazolesFluconazoleMucormycosisVoriconazoleHumans

Stichwörter der Autor:innen

amino acid substitutionantifungal resistancemucoralesresistance mechanism

Substanzen

Antifungal AgentsAzolesSterol 14-DemethylaseposaconazoleFungal ProteinsTriazolesFluconazoleVoriconazole

Autor:innen und Institutionen

  • Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
  • Faculty of Dentistry, Sir John Walsh Research Institute, University of Otago, Dunedin, Otago, New Zealand.
  • Departamento de Genética y Microbiología, Facultad de Biología, Universidad de Murcia, Murcia, Spain.
  • Department of Pharmacy - Center for Drug Research, Ludwig-Maximilians Universität München, Munich, Bavaria, Germany.
  • Department of Chemistry, Biology and Biotechnology, Università degli Studi di Perugia, Perugia, Umbria, Italy.
  • School of Pharmacy, University of Otago, Dunedin, Otago, New Zealand.

ORCID-Profile: Michaela Lackner, Stephanie Toepfer, Victoriano Garre, Christoph Müller, Brian C Monk

Förderung

  • Fundación Séneca
  • Health Research Council of New Zealand
  • Royal Society of New Zealand
  • Austrian Science Fund
  • European Regional Development Fund
  • Agencia Estatal de Investigación

Zitieren

APA

Lackner, M., Toepfer, S., Keniya, M. V., Lax, C., Nicolas, F. E., Garre, V., Müller, C., Rosam, K., Zenz, L. M., Cesarini, L., Binder, U., Tyndall, J. D. A., & Monk, B. C. (2026). The molecular basis of intrinsic resistance to azoles in Rhizopus arrhizus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01337-25

Vancouver

Lackner M, Toepfer S, Keniya MV, Lax C, Nicolas FE, Garre V, et al. The molecular basis of intrinsic resistance to azoles in Rhizopus arrhizus. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01337-25

BibTeX
@article{Lackner2026,
  author = {Lackner, Michaela and Toepfer, Stephanie and Keniya, Mikhail V and Lax, Carlos and Nicolas, Francisco E and Garre, Victoriano and Müller, Christoph and Rosam, Katharina and Zenz, Lisa-Maria and Cesarini, Lucia and Binder, Ulrike and Tyndall, Joel D A and Monk, Brian C},
  title = {The molecular basis of intrinsic resistance to azoles in Rhizopus arrhizus},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2026},
  doi = {10.1128/aac.01337-25}
}
Kostenlos starten →